Alfasigma S.p.A., has entered into a share purchase agreement with Sever Life Sciences for the sale of 100% of the shares of Nordic Group B.V. (Nordic Pharma) and its subsidiaries.

The acquisition will add Nordic Pharma’s ophthalmology portfolio, including its Lacrifill Canalicular Gel for the treatment of dry eye. Lacrifill is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system and is indicated for up to 6 months of use.  

Nordic Pharma’s Biolon and Biolon Prime ophthalmic viscoelastic devices are also included in the acquisition. 

According to the press release, the acquisition will also add Nordic Pharma’s rheumatoid arthritis business, led by the Nordimet methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca franchise. It will also expand Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to ophthalmology and rheumatology, the acquisition will also include Nordic Pharma’s portfolio in women’s health and critical care.